Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial
Abstract
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton's tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinical responses to ibrutinib could be deepened by DEX and the JAK inhibitor ruxolitinib. Patients on ibrutinib at 420 mg daily for 2 months or with abnormal serum β2M levels after 6 months or with...
Paper Details
Title
Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial
Published Date
Nov 17, 2021
Journal
Volume
10
Issue
24
Pages
8789 - 8798
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History